Public Health, Pharmacoepidemiology & Digital Health: RWE, NCD Prevention & Patient-Centred Systems for Horizon Europe

As an MD, PhD at Marmara University’s Institute of Population and Social Research, I provide interdisciplinary research leadership bridging Life Sciences (Cluster 1: Health) and Social Sciences & Humanities (SSH).

My expertise combines real-world data (RWD) analytics, pharmacoepidemiology, primary healthcare models, and behavioral/infodemiology insights. I actively contribute as an Independent Expert and Rapporteur for the European Research Executive Agency (REA - MSCA) and as a Senior Collaborator in the Global Burden of Disease (GBD) study (IHME), offering consortia strong methodological rigor, evaluation awareness, and high-impact policy translation.

Targeted Expertise Mapped to Selected Calls

1. HORIZON-HLTH-2027-01-CARE-02: Personalised Approaches to Reduce Risks from ADRs Caused by Taking Multiple Medications

• Pharmacoepidemiology & Polypharmacy: Deep track record in analyzing primary care electronic registries, claims data, and real-world prescribing patterns (e.g., inappropriate prescribing, Beers criteria application in older and multimorbid populations, medication adherence in long-term therapy).

• Adverse Drug Reactions (ADR) & Prescribing Quality: Comparative pharmacotherapy studies, rational use of medicines (RUM), and risk prediction models to identify patient sub-cohorts at elevated risk of ADRs and drug-drug interactions.

2. HORIZON-HLTH-2027-01-DISEASE-10: Prevention and Management of Chronic NCDs in Children and Young People (GACD)

• Early-Life & Youth Chronic Disease Dynamics: Investigation of type 1 and type 2 diabetes disparities, cardiovascular risk trajectories, metabolic indicators, and health literacy in younger cohorts.

• Digital Health & Youth Engagement: Active researcher in the Erasmus+ KA220-YOU project (MOSAIC - 2025–2028), developing innovative digital awareness and training frameworks for youth.

• Behavioral & Preventative Interventions: Extensive expertise in lifestyle interventions, addiction prevention frameworks, and school/community-based public health program designs.

3. HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing Disabilities Through the Life Course to Support Independent Living and Inclusion

• Life-Course Epidemiology & Disease Burden: Multi-country epidemiological modeling of chronic impairments, sensory/functional losses, and non-communicable disease trajectories through the GBD framework.

• Health Systems & Aging Policies: Research on institutional and individual health literacy, community/home-based health services evaluation, and demographic transitions impacting independent living.

• Social Determinants & Social Inclusion (SSH): Integrating social inequality metrics, caregiver burdens, and vulnerability dynamics into clinical and assistive technology interventions to ensure broad accessibility and equity.

Role in Consortia & Work Package Contributions

• WP Lead / Co-Lead on Study Design & Quantitative Methodology: Observational cohort design, secondary registry/claims analysis, biostatistics, survey implementation, and epidemiological modeling.

• SSH-Life Sciences Integration: Bridging clinical endpoints with patient-reported outcomes, social determinants of health, digital behavior analytics, and stakeholder engagement.

• Translation, Policy Roadmaps & Guidelines: Converting complex clinical and pharmacoepidemiological evidence into concrete guidelines, policy briefs, and practitioner training packages.

• Quality Assurance & Proposal Alignment: Applying EU Commission evaluation criteria, impact pathway framing, and consortium coherence drawn from REA rapporteur and expert experience.